Pre-specified secondary endpoint showed 0-11 vaccine to placebo case split for medically attended C. difficile infection (CDI), corresponding to 100% vaccine efficacy Median CDI duration was 1 versus ...

Clostridioides difficile has been traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...

Pfizer (NYSE:PFE) is trading lower in the pre-market Tuesday after the company announced that its pivotal Phase 3 study for Clostridioides difficile vaccine candidate (PF-06425090) did not meet the ...

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

University of Pennsylvania and Children's Hospital of Philadelphia researchers have developed the first mRNA Clostridioides difficile vaccine — and it's shown promising results in animal models.

(RTTNews) - Pfizer Inc. (PFE) said Tuesday that the CLOVER trial, a pivotal Phase 3 study evaluating its Clostridioides difficile vaccine candidate (PF-06425090) in the prevention of C. difficile ...

Oct 18 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive it in your inbox for free sign up here, opens new ...

I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and ...

PHILADELPHIA — The same technology that saved millions of lives during the COVID-19 pandemic appears to hold promise against another scourge of infectious disease, according to new research from the ...